European Commission Approves BLINCYTO ® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
BLINCYTO is the First and Only Therapy for Minimal Residual Disease Approved in the European Union
Approval Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia
THOUSAND OAKS, Calif., Jan. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative (Ph-) CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission ...
Source: Amgen News Release - January 22, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
No substantial benefit from transplantation reported for a high-risk leukemia subtype
(St. Jude Children's Research Hospital) Study led by St. Jude Children's Research Hospital found treatment guided by measuring minimal residual disease was associated with better outcomes for hypodiploid acute lymphoblastic leukemia patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 18, 2019 Category: Cancer & Oncology Source Type: news
Family of a cancer-stricken girl have sparked up a friendship with the 'angel' who saved her life
Skylah Ballentine-Brain, now eight, was diagnosed with acute lymphoblastic leukaemia at less than one-year-old, while her family were living in Cape Town. She was forced to endure chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - January 7, 2019 Category: Consumer Health News Source Type: news
Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel® (dasatinib) tablets to include the treatment of pediatric patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 2, 2019 Category: Drugs & Pharmacology Source Type: news
HEALTH NOTES: Ellie Mae stars as Santa after beating cancer
Ellie Mae Wile-Dunne (pictured), who was diagnosed with the the blood cancer acute lymphoblastic leukaemia when she was four, is starring in cancer charity CLIC Sargent ’s online ad. (Source: the Mail online | Health)
Source: the Mail online | Health - December 22, 2018 Category: Consumer Health News Source Type: news
FDA Approves Two New Drugs for ALL and BPDCN FDA Approves Two New Drugs for ALL and BPDCN
The FDA has granted approval for a drug to be used in acute lymphoblastic leukemia and the first treatment approved for blastic plasmacytoid dendritic cell neoplasm.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves New Enzyme Product for ALL FDA Approves New Enzyme Product for ALL
The FDA has granted approval for a new enzyme product, calaspargase pegol-mknl, to be used in acute lymphoblastic leukemia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Asparlas (calaspargase pegol-mknl) for Acute Lymphoblastic Leukemia (ALL)
On December 20, 2018, the Food and Drug Administration approved calaspargase pegol-mknl (ASPARLAS, Servier Pharmaceuticals LLC), an asparagine specific enzyme, as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 20, 2018 Category: Drugs & Pharmacology Source Type: news
NSU researchers uncover genetic marker, predictor of early relapse in pediatric ALL
(Nova Southeastern University) Researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia (ALL) patients. This (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 13, 2018 Category: Cancer & Oncology Source Type: news
Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO ® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
First and Only EU Marketing Authorization Application to Include Presence of Minimal Residual Disease
Application Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia
THOUSAND OAKS, Calif., Nov. 16, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for BLINCYTO® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative CD19 pos...
Source: Amgen News Release - November 16, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018
First-in-Human Data Evaluating AMG 420 in Multiple Myeloma and AMG 330 in Acute Myeloid Leukemia Underscore Potential of BiTE® Immunotherapy Platform Across Hematologic Malignancies
BLINCYTO® (blinatumomab) Long-Term Data Demonstrate Benefits of Achieving Complete MRD Response in Adult Patients With Acute Lymphoblastic Leukemia and Reinforce BiTE® Proof-of-Concept
Data From Multiple Myeloma Research Foundation CoMMpass Trial of KYPROLIS® (carfilzomib) in Newly Diagnosed Multiple Myeloma Patients to be Presented at ASH
THOUSAND OAKS, Calif., Nov. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that ...
Source: Amgen News Release - November 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Low-fat diet increases cancer survival rate in mice, study finds
Something as simple as a change in diet can potentially help to increase the cancer survival rate of obese children with acute lymphoblastic leukemia, the most common childhood cancer, according to a new study by UCLA scientists.The research team, led by Dr. Steven Mittelman, chief of pediatric endocrinology at UCLA Mattel Children ’s Hospital and member of the UCLA Jonsson Comprehensive Cancer Center, administered the chemotherapy drug vincristine to obese and non-obese mice with leukemia. Researchers discovered that if they switched the obese mice from a high-fat to a low-fat diet immediately before starting chemo...
Source: UCLA Newsroom: Health Sciences - November 1, 2018 Category: Universities & Medical Training Source Type: news
High hospital costs for acute lymphoblastic leukaemia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2018 Category: Drugs & Pharmacology Source Type: news
Low-fat diet increases cancer survival rate in mice, study finds
(University of California - Los Angeles Health Sciences) Something as simple as a change in diet can potentially help to increase the cancer survival rate of obese children with acute lymphoblastic leukemia, the most common childhood cancer, according to a new study by UCLA scientists. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 31, 2018 Category: Cancer & Oncology Source Type: news
Birth Weight and Risk of Childhood ALL Birth Weight and Risk of Childhood ALL
This study confirms a previously reported association between high birth weight and the risk of developing childhood acute lymphoblastic leukemia. How might this relate to ethnicity and maternal diet?Southern Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 26, 2018 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news
